LGALS9 and neoplasm: The therapeutic efficacy of human MSCs can be reproduced by the administration of their autologous exosomes.99 Moreover, genetic engineering modified MSC-derived exosomes can act as ‘Trojan horses’ to target the tumor microenvironment and strengthen tumor immunotherapy.100 Such exosomes are constructed to carry galectin-9 siRNA and oxaliplatin pro-drug.